SonALAsense, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.sonalasense.com
A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
Phase 1
Terminated
- Conditions
- Recurrent GBM
- Interventions
- Combination Product: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- SonALAsense, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05370508
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients With DIPG
Phase 2
Terminated
- Conditions
- Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma
- Interventions
- Combination Product: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- SonALAsense, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05123534
- Locations
- 🇺🇸
Children's National / Children's Research Institute, Washington, District of Columbia, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath